Can We Miss Pigmented Lesions in Psoriasis Patients?
In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However, successful systemic treatment and subsequent clearing of psoriatic plaques may allow clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of early identification and treatment of suspicious lesions such as nonmelanoma skin cancer and malignant melanoma.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Can We Miss Pigmented Lesions in Psoriasis Patients?|
- The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. [ Time Frame: Patients will complete study within 6 months. ] [ Designated as safety issue: No ]
- A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria [ Time Frame: Patients will complete the study within 6 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||September 2007|
|Study Completion Date:||April 2012|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
Other Name: Enbrel
No further description is desired.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01053819
|United States, Alabama|
|Birmingham, Alabama, United States, 35233|
|Principal Investigator:||Boni E Elewski, MD||University of Alabama at Birmingham|